* Oncorus Inc ONCR.OQ ONCR.O is expected to show no
change in
quarterly revenue when it reports results on March 7
(estimated).
*
* Refinitiv's mean analyst estimate for Oncorus Inc is for
a loss
of 76 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Oncorus Inc
is
$3.5, above its last closing price of $0.39.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.80 -0.75 -0.76 Missed -0.9
Jun. 30 2022 -0.73 -0.72 -0.74 Missed -2.3
Mar. 31 2022 -0.78 -0.77 -0.69 Beat 10.4
Dec. 31 2021 -0.69 -0.77 Missed -11.6
Sep. -0.65 -0.64 -0.65 Missed -2.1
30 2021
Jun. 30 2021 -0.57 -0.56 -0.60 Missed -6.5
Mar. 31 2021 -0.53 -0.53 -0.53 Met 0.9
Dec. 31 2020 -0.48 -0.48 -0.56 Missed -15.5
This summary was machine generated March 3 at 12:06 GMT. All
figures in US dollars unless otherwise stated